$1.8bn merger unites Supernus and Indivior
Supernus Pharmaceuticals and Indivior agreed to merge in a deal valued at about $1.8 billion. Indivior shareholders will receive 0.2683 Supernus shares each, a stated ~58% premium. Supernus shareholders will own ~58% and Indivior ~42%. Closing is expected in H2 2026, pending approvals, with ~$125 million annual cost synergies by end-2027.
How this was made
The 30-second read
Why it matters
For traders, the key actionable inputs are the 0.2683 exchange ratio, the ~58% premium, the expected H2 2026 closing window, and the $125m annual cost synergy target by end-2027, all of which drive merger-arb pricing and risk premia.
Market read
A disclosed merger with a large stated premium and quantified synergy targets is likely to move deal spreads and influence near-term positioning for both companies.
What to watch
Regulatory approval path is the dominant variable, and the article does not specify which jurisdictions or agencies are expected to review, nor any antitrust or product-specific risks.
Background
The article describes a proposed $1.8bn merger between Supernus Pharmaceuticals and Indivior, including the share exchange ratio, ownership split, leadership, and synergy plan.
Ticker impact
Supernus is the acquirer in a $1.8bn merger, issuing 0.2683 shares per Indivior share and expecting close in H2 2026.
Likely supportive near-term for deal-spread and merger-arb positioning, with volatility around regulatory approval risk.
The article provides concrete exchange ratio, ownership split, synergy estimate, and expected timing, which are key inputs for merger-arb and risk premia.
Indivior shareholders will receive 0.2683 SUPN shares per INDV share, implying a ~58% premium and shifting INDV’s deal risk profile.
Supportive for INDV on deal premium, but downside tail exists if approvals stall or terms change.
The article discloses the premium, exchange ratio, and synergy-driven rationale, which directly affect INDV valuation and merger-arb spreads.
Market effects
Consolidation in CNS and addiction therapeutics could intensify M&A expectations and competition for pipeline assets.
Limited direct regional impact; HQ remains in Rockville, Maryland.
Moderate, as the deal is US-focused but may influence global CNS M&A sentiment and investor appetite for specialty pharma roll-ups.
Counterpoint
The stated $125m cost synergies and EBITDA timing may be optimistic; if integration costs or regulatory delays rise, merger spreads can widen quickly.
Key entities
- public_companySupernus Pharmaceuticals
Acquirer in the proposed merger; will issue shares and is expected to be the surviving entity named Supernus, Inc.
- public_companyIndivior
Target in the proposed merger; shareholders receive 0.2683 SUPN shares per INDV share and hold ~42% of the combined company.
- executiveJack Khattar
Named as president and CEO of the combined entity.
